Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Other Working Capital Changes (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Other Working Capital Changes for 13 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 78.45% to -$1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.0 million through Dec 2025, up 219.84% year-over-year, with the annual reading at $34.0 million for FY2025, 219.84% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was -$1.5 million at Madrigal Pharmaceuticals, up from -$9.3 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was $35.4 million in Q2 2025, with the low at -$9.3 million in Q3 2025.
  • Average Other Working Capital Changes over 5 years is $2.3 million, with a median of $480000.0 recorded in 2023.
  • Peak annual rise in Other Working Capital Changes hit 10096.61% in 2024, while the deepest fall reached 22209.38% in 2024.
  • Over 5 years, Other Working Capital Changes stood at -$2.5 million in 2021, then soared by 46.44% to -$1.3 million in 2022, then soared by 102.42% to $32000.0 in 2023, then tumbled by 22209.38% to -$7.1 million in 2024, then soared by 78.45% to -$1.5 million in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at -$1.5 million, -$9.3 million, and $35.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.